RESUMEN
Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-ß-cyclodextrin (HPßCD) inclusion complexes' formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPßCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPßCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPßCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration.
RESUMEN
Inflammatory Bowel Disease (IBD) is a group of chronic disorders of the gastrointestinal tract, which two main types are Crohn's disease and ulcerative colitis. Although conventional therapeutic strategies have demonstrated to be effective in the IBD treatment, it is necessary to incorporate novel therapeutic agents that target other mechanisms involved in the pathogenesis of the disease, such as oxidative stress. For this reason, the efficacy in vivo of two antioxidant compounds, melatonin and resveratrol, has been investigated in an animal model of TNBS (2, 4, 6-trinitrobenzenesulfonic acid) induced colitis. PET/CT (Positron emission tomography/Computer Tomography) scans were performed to assess disease activity and evaluate treatment response. SUVmax (Standardized Uptake Value) values, body weight changes and histological evaluation were used as inflammatory indices to measure the efficacy of both treatments. SUVmax values increased rapidly after induction of colitis, but after the beginning of the treatment (day 3) a statistically significant decrease was observed on days 7 and 10 in treated animals compared to the non-treated group. This remission of the disease was also confirmed by histological analysis of the colon tissue using the Nancy histological index (p valueâ¯<â¯0.05 for differences between non-treated and both groups of treated animals). Moreover, statistical analysis showed a correlation (R2â¯=â¯65.52%) between SUVmax values and weight changes throughout the treatment. Overall, this study demonstrates the potential of resveratrol, and melatonin in lower extent, as therapeutic agents in the IBD treatment.
Asunto(s)
Antioxidantes/administración & dosificación , Colitis/tratamiento farmacológico , Melatonina/administración & dosificación , Resveratrol/administración & dosificación , Animales , Colitis/inducido químicamente , Colitis/diagnóstico por imagen , Colitis/patología , Colon/diagnóstico por imagen , Colon/efectos de los fármacos , Colon/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones , Ratas Sprague-Dawley , Ácido TrinitrobencenosulfónicoRESUMEN
Mucopolysaccharidosis IVA (Morquio A) is a rare inherited metabolic disease caused by deficiency of the lysosomal enzyme N-acetylgalatosamine-6-sulfate-sulfatase (GALNS). Until now, treatments employed included hematopoietic stem cell transplantation and enzyme replacement therapy (ERT); the latter being the most commonly used to treat mucopolysaccharidoses, but with serious disadvantages due to rapid degradation and clearance. The purpose of this study was to develop and evaluate the potential of nanostructured lipid carriers (NLCs) by encapsulating elosulfase alfa and preserving its enzyme activity, leading to enhancement of its biological effect in chondrocyte cells. A pegylated elosulfase alfa-loaded NLC was characterized in terms of size, ζ potential, structural lipid composition (DSC and XRD), morphology (TEM microscopy), and stability in human plasma. The final formulation was freeze-dried by selecting the appropriate cryoprotective agent. Viability assays confirmed that NLCs were non-cytotoxic to human fibroblasts. Imaging techniques (confocal and TEM) were used to assess the cellular uptake of NLCs loaded with elosulfase alfa. This study provides evidence that the encapsulated drug exhibits enzyme activity inside the cells. Overall, this study provides a new approach regarding NLCs as a promising delivery system for the encapsulation of elosulfase alfa or other enzymes and the preservation of its activity and stability to be used in enzymatic replacement therapy (ERT).
RESUMEN
: Intra-articular administration of drugs to the joint in the treatment of joint disease has the potential to minimize the systemic bioavailability and the usual side-effects associated with oral drug administration. In this work, a drug delivery system is proposed to achieve an anti-inflammatory local effect using resveratrol (RSV). This study aims to develop microcapsules made of poly-(ε-caprolactone) (PCL) by ultrasonic atomization to preserve the antioxidant activity of RSV, to prevent its degradation and to suppress the inflammatory response in activated RAW 264.7 macrophages. An experimental design was performed to build a mathematical model that could estimate the effect of nozzle power and polymer concentration on particle size and encapsulation efficiency. RSV-loaded microcapsules showed adequate morphology, particle size, and loading efficiency properties. RSV formulations exhibited negligible cytotoxicity and an efficient amelioration of inflammatory responses, in terms of Nitric Oxide (NO), ROS (Reactive Oxygen Species), and lipid peroxidation in macrophages. Thus, RSV-loaded microcapsules merit consideration as a drug delivery system suitable for intra-articular administration in inflammatory disorders affecting the joint.
RESUMEN
Econazole is a feasible alternative treatment in the management of fungal keratitis. Nevertheless, its low water solubility is considered the main limitation to the incorporation into ophthalmic formulations. In this work, econazole nitrate is solubilized by using cyclodextrins to achieve an optimum therapeutic concentration. Phase solubility diagrams suggest α-cyclodextrin as the most effective cyclodextrin and later the inclusion complex formed with this one was characterized in solution by 1D, 2D-NMR, and molecular modeling. Econazole-α-cyclodextrin inclusion complex was included in 2 types of ocular hydrogels: a natural polysaccharides ion-sensitive hydrogel and a hyaluronic acid hydrogel. Both of them show no ocular irritation in the hen's egg test on chorioallantoic membrane assay and a controlled econazole release over time. Permeability studies suggest that hydrogels do not modify the econazole nitrate permeability through bovine cornea in comparison with an econazole-α-cyclodextrin inclusion complex solution. Finally, ocular biopermanence studies performed using positron emission tomography show these hydrogels present a high retention time on the eye. Results suggest the developed formulations have a high potential as vehicles for the econazole topical ocular administration as fungal keratitis treatment.
Asunto(s)
Antifúngicos/administración & dosificación , Preparaciones de Acción Retardada/química , Econazol/administración & dosificación , Hidrogeles/química , Queratitis/tratamiento farmacológico , alfa-Ciclodextrinas/química , Administración Oftálmica , Animales , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Bovinos , Pollos , Córnea/metabolismo , Córnea/microbiología , Composición de Medicamentos , Econazol/farmacocinética , Econazol/farmacología , Hongos/efectos de los fármacos , Queratitis/metabolismo , Queratitis/microbiología , SolubilidadRESUMEN
La cistinosis ocular es una enfermedad rara que se caracteriza por el depósito de cristales de cistina a nivel corneal, los cuales dificultan la visión de los pacientes. La cisteamina oral se administra en forma de cisteamina, pero esta no alcanza la córnea debido a la falta de vascularización corneal, por lo que es necesaria la aplicación tópica ocular. El objetivo del presente trabajo es determinar la estabilidad de un hidrogel oftálmico de cisteamina, potencialmente formulable en servicios de farmacia hospitalaria, conservado este bajo diferentes condiciones de almacenamiento durante un periodo de 30 días. Los parámetros físicos y químicos evaluados han sido la osmolalidad, el pH y la concentración de cisteamina, siendo esta última valorada mediante un método de cromatografía líquida de ultra alta presión, empleando un detector de masas en tándem (UPLC-MS/MS). Los ensayos descriptivos se han basado en la medición de la transparencia y los ensayos microbiológicos en la realización de pruebas de esterilidad. Los resultados obtenidos permiten concluir que el hidrogel de cisteamina es estable durante un periodo de 30 días, recomendándose que su conservación sea en nevera (AU)
Ocular cystinosis is a rare disease characterised by the deposit of cystine crystals on the corneal surface, which hinder patients' eyesight. Oral cysteamine is given as cysteamine; however, it does not reach the cornea due to the lack of corneal vascularization making necessary its administration by the topical ocular route. The aim of the present study is to determine the stability of an ophthalmic hydrogel of cysteamine, which can be potentially prepared at hospital pharmacy departments, under different preservation conditions during a follow-up of 30 days. Different physical and chemical parameters were evaluated: osmolality, pH and cysteamine concentration, which has been measured by a method of ultra performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS). Descriptive assays were also performed, such as transparency measurement and microbiological assays in order to verify its sterility. The obtained results allow us to conclude that the cysteamine hydrogel is stable during 30 days, being recommendable its preservation in refrigerated conditions (AU)
Asunto(s)
Humanos , Hidrogeles/uso terapéutico , Cistinosis/tratamiento farmacológico , Enfermedades de la Córnea/tratamiento farmacológico , Ácido Hialurónico/uso terapéutico , Espectrometría de Masas/métodos , Ácido Ditionitrobenzoico/uso terapéutico , 28599RESUMEN
Ocular cystinosis is a rare disease characterised by the deposit of cystine crystals on the corneal surface, which hinder patients' eyesight. Oral cysteamine is given as cysteamine; however, it does not reach the cornea due to the lack of corneal vascularization making necessary its administration by the topical ocular route. The aim of the present study is to determine the stability of an ophthalmic hydrogel of cysteamine, which can be potentially prepared at hospital pharmacy departments, under different preservation conditions during a follow-up of 30 days. Different physical and chemical parameters were evaluated: osmolality, pH and cysteamine concentration, which has been measured by a method of ultra performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS). Descriptive assays were also performed, such as transparency measurement and microbiological assays in order to verify its sterility. The obtained results allow us to conclude that the cysteamine hydrogel is stable during 30 days, being recommendable its preservation in refrigerated conditions.
La cistinosis ocular es una enfermedad rara que se caracteriza por el depósito de cristales de cistina a nivel corneal, los cuales dificultan la visión de los pacientes. La cisteamina oral se administra en forma de cisteamina, pero esta no alcanza la córnea debido a la falta de vascularización corneal, por lo que es necesaria la aplicación tópica ocular. El objetivo del presente trabajo es determinar la estabilidad de un hidrogel oftálmico de cisteamina, potencialmente formulable en servicios de farmacia hospitalaria, conservado este bajo diferentes condiciones de almacenamiento durante un periodo de 30 días. Los parámetros físicos y químicos evaluados han sido la osmolalidad, el pH y la concentración de cisteamina, siendo esta última valorada mediante un método de cromatografía líquida de ultra alta presión, empleando un detector de masas en tándem (UPLC-MS/MS). Los ensayos descriptivos se han basado en la medición de la transparencia y los ensayos microbiológicos en la realización de pruebas de esterilidad. Los resultados obtenidos permiten concluir que el hidrogel de cisteamina es estable durante un periodo de 30 días, recomendándose que su conservación sea en nevera.
Asunto(s)
Cisteamina/administración & dosificación , Cisteamina/uso terapéutico , Cistinosis/tratamiento farmacológico , Oftalmopatías/tratamiento farmacológico , Hidrogel de Polietilenoglicol-Dimetacrilato/administración & dosificación , Hidrogel de Polietilenoglicol-Dimetacrilato/uso terapéutico , Soluciones Oftálmicas/administración & dosificación , Soluciones Oftálmicas/uso terapéutico , Administración Tópica , Química Farmacéutica , HumanosRESUMEN
Cystinosis is a rare autosomal recessive disorder in which cystine crystals accumulate within the lysosomes of various organs, including the cornea. Ocular treatment is based on the administration of cysteamine eye drops, requiring its instillation several times per day. We have introduced the cysteamine in two types of previously developed ocular hydrogels (ion sensitive hydrogel with the polymers gellan gum and kappa-carrageenan and another one composed of hyaluronic acid), aiming at increasing the ocular retention in order to extend the dosing interval. The biopermanence studies (direct measurements and PET/CT) show that these formulations present a high retention time on the ocular surface of rats. From the in vitro release study we determined that both hydrogels can control the release of cysteamine over time, showing a zero order kinetics during four hours. At the same time, these hydrogels could act as corneal absorption promoters, as they allow a higher permeation of cysteamine through bovine cornea compared to a solution. HET-CAM test and cytotoxicity assays show no irritation on the ocular surface. These results demonstrate that the developed formulations present a high potential as vehicles for the topical ocular administration of cysteamine.
Asunto(s)
Cisteamina/administración & dosificación , Preparaciones de Acción Retardada/química , Portadores de Fármacos/química , Hidrogeles/química , Administración Oftálmica , Animales , Carragenina/química , Bovinos , Células Cultivadas , Queratocitos de la Córnea/efectos de los fármacos , Cistinosis/tratamiento farmacológico , Humanos , Masculino , Polisacáridos Bacterianos/química , Tomografía Computarizada por Tomografía de Emisión de Positrones , Ratas , Ratas Sprague-DawleyRESUMEN
Purpose: This work aimed at describing the time course of vitreous clearance through the use of positron emission tomography (PET) as a noninvasive tool for pharmacokinetic studies of intravitreal injection. Methods: The pharmacokinetic profile of intravitreal injections of molecules labeled with 18Fluorine (18F) was evaluated in adult Sprague Dawley rats by using a dedicated small-animal PET/computed tomography scanner. Different conditions were studied: three molecules radiolabeled with 18F (18F-FDG, 18F-NaF, and 18F-Choline), three volumes of intravitreal injections (7, 4, and 2 µL), and absence or presence of eye inflammation (uveitis). Results: Our results showed that there are significant pharmacokinetic differences among the radiolabeled molecules studied but not among the injected volumes. The presence or absence of uveitis was an important factor in vitreous clearance, since the elimination of the drug was clearly increased when this condition is present. Conclusions: Intravitreal pharmacokinetic studies based on the use of dedicated PET imaging can be of potential interest as noninvasive tools in ophthalmic drug development in small animals.
Asunto(s)
Fluorodesoxiglucosa F18/administración & dosificación , Tomografía de Emisión de Positrones/métodos , Uveítis/metabolismo , Cuerpo Vítreo/metabolismo , Animales , Modelos Animales de Enfermedad , Fluorodesoxiglucosa F18/farmacocinética , Inyecciones Intravítreas , Masculino , Radiofármacos/administración & dosificación , Radiofármacos/farmacocinética , Ratas , Ratas Sprague-Dawley , Uveítis/diagnóstico , Cuerpo Vítreo/patologíaRESUMEN
In last years, sensitive hydrogels have become a breakthrough in ophthalmic pharmaceutical technology aimed at developing new strategies to increase the residence time of active substances. In a previous paper, we qualitatively demonstrated the capacity of a new ion sensitive hydrogel to increase the residence time. Nevertheless, the clearance of the gel from the ocular surface was not quantifiable with the used methodology. The aim of the present work was to use a well-established approach based on scintigraphy to quantitatively estimate the residence time of the previously proposed hydrogel. The rat corneal residence time of a topic ophthalmic formulation containing gellan gum and kappa carragenan (0.82% w/v) labeled with 99mTc-DTPA radiotracer was evaluated and compared with the residence of an aqueous solution. Ophthalmic safety studies such as eye irritation or passage through the cornea were also carried out. After 1.5h of contact, 77% of the hydrogel remained in the ocular surface, presenting kinetics of disappearance one-phase decay and a half time of 262min. We conclude that the novel ophthalmic hydrogel developed with kappa carrageenan and gellan gum remains for long periods of time on the corneal surface, presenting a drop that fits an exponential decay.
Asunto(s)
Carragenina/química , Córnea/metabolismo , Hidrogeles/química , Polisacáridos Bacterianos/química , Animales , Carragenina/efectos adversos , Córnea/diagnóstico por imagen , Composición de Medicamentos , Excipientes/química , Hidrogeles/efectos adversos , Irritantes , Marcaje Isotópico , Masculino , Soluciones Oftálmicas , Polisacáridos Bacterianos/efectos adversos , Cintigrafía , Radiofármacos/química , Ratas , Ratas Sprague-DawleyRESUMEN
Purpose: This work is aimed at describing the utility of positron emission tomography/computed tomography (PET/CT) as a noninvasive tool for pharmacokinetic studies of biopermanence of topical ocular formulations. Methods: The corneal biopermanence of a topical ophthalmic formulation containing gellan gum and kappa carragenan (0.82% wt/vol) labeled with 18Fluorine (18F) radiotracers (18F-FDG and 18F-NaF) was evaluated by using a dedicated small-animal PET/CT, and compared with the biopermanence of an aqueous solution labeled with the same compounds. Regions of interest (ROIs) were manually drawn on the reconstructed PET images for quantifying the radioactivity concentration in the eye. The biopermanence of the formulations was determined by measuring the radioactivity concentration at different times after topical application. Additionally, cellular and ex vivo safety assays were performed to assess the safety of the performed procedures. Results: Differences were observed in the ocular pharmacokinetics of the two formulations. After 1.5 hours of contact, 90% of the hydrogel remained in the ocular surface, while only 69% of the control solution remained. Furthermore, it was observed that flickering had a very important role in the approach of the trial. The application of 18F-FDG in the eye was neither irritating nor cytotoxic for human corneal epithelial cells. Conclusions: The use of small-animal PET and 18F radiotracers in ocular pharmacokinetics of ophthalmic formulations is feasible and could be a safe method for future ocular pharmacokinetic studies in humans.
Asunto(s)
Córnea/metabolismo , Hidrogel de Polietilenoglicol-Dimetacrilato/farmacocinética , Soluciones Oftálmicas/farmacocinética , Tomografía Computarizada por Tomografía de Emisión de Positrones , Animales , Carragenina/farmacocinética , Córnea/efectos de los fármacos , Sistemas de Liberación de Medicamentos/métodos , Fluorodesoxiglucosa F18/administración & dosificación , Fluorodesoxiglucosa F18/toxicidad , Humanos , Hidrogel de Polietilenoglicol-Dimetacrilato/química , Masculino , Polisacáridos Bacterianos/farmacocinética , Radiofármacos/administración & dosificación , Radiofármacos/toxicidad , Ratas , Ratas Sprague-DawleyRESUMEN
The use of parenteral antibiotic eye drop formulations with non-marketed compositions or concentrations, commonly called fortified antibiotic eye drops, is a common practice in Ophthalmology in the hospital setting. The aim of this study was to evaluate the in vitro ocular toxicity of the main fortified antibiotic eye drops prepared in the Hospital Pharmacy Departments. We have conducted an in vitro experimental study in order to test the toxicity of gentamicin, amikacin, cefazolin, ceftazidime, vancomycin, colistimethate sodium and imipenem-cilastatin eye drops; their cytotoxicity and acute tissue irritation have been evaluated. Cell-based assays were performed on human stromal keratocytes, using a cell-based impedance biosensor system [xCELLigence Real-Time System Cell Analyzer (RTCA)], and the Hens Egg Test for the ocular irritation tests. All the eye drops, except for vancomycin and imipenem, have shown a cytotoxic effect dependent on concentration and time; higher concentrations and longer exposure times will cause a steeper decline in the population of stromal keratocytes. Vancomycin showed a major initial cytotoxic effect, which was reverted over time; and imipenem appeared as a non-toxic compound for stromal cells. The eye drops with the highest irritating effect on the ocular surface were gentamicin and vancomycin. Those antibiotic eye drops prepared at the Hospital Pharmacy Departments included in this study were considered as compounds potentially cytotoxic for the ocular surface; this toxicity was dependent on the concentration used (AU)
El uso de reformulaciones de antibióticos parenterales en forma de colirios de composición o concentraciones no comercializadas, comúnmente denominados colirios antibióticos reforzados, es una práctica habitual en oftalmología a nivel hospitalario. El objetivo del presente trabajo ha consistido en evaluar la toxicidad ocular in vitro de los principales colirios antibióticos reforzados elaborados en los Servicios de Farmacia Hospitalaria. Hemos realizado un estudio experimental in vitro para evaluar la toxicidad de los colirios de gentamicina, amikacina, cefazolina, ceftazidima, vancomicina, colistimetato de sodio e imipenem-cilastatina en el que se ha evaluado su citotoxicidad y la irritación tisular aguda. Los ensayos celulares se realizan sobre queratocitos estromales humanos, mediante la utilización de un sistema biosensor de impedancia celular [(xCELLigence Real-Time System Cell Analyzer (RTCA)] y los ensayos de irritación ocular mediante el ensayo Hen´s Egg Test. Todos los colirios, excepto vancomicina e imipenem, han mostrado un efecto citotóxico de concentración y tiempo dependiente, siendo las concentraciones más altas y los tiempos más prolongados los que provocan un descenso más pronunciado en la población de queratocitos estromales. La vancomicina muestra un importante efecto citotóxico inicial que revierte con el transcurso del tiempo y el imipenem se muestra como un compuesto no tóxico para las células estromales. Los compuestos con mayor efecto irritante para la superficie ocular son la gentamicina y la vancomicina. Los colirios antiinfecciosos elaborados en los Servicios de Farmacia Hospitalaria estudiados se muestran como compuestos potencialmente citotóxicos para la superficie ocular, siendo esta toxicidad dependiente de la concentración utilizada (AU)
Asunto(s)
Humanos , Soluciones Oftálmicas/toxicidad , Antibacterianos/toxicidad , Servicio de Farmacia en Hospital/estadística & datos numéricos , Preparaciones Farmacéuticas/análisis , Citotoxicidad Inmunológica , Aminoglicósidos/toxicidad , beta-Lactamas/toxicidad , Glicopéptidos/toxicidadRESUMEN
The use of parenteral antibiotic eye drop formulations with non-marketed compositions or concentrations, commonly called fortified antibiotic eye drops, is a common practice in Ophthalmology in the hospital setting. The aim of this study was to evaluate the in vitro ocular toxicity of the main fortified antibiotic eye drops prepared in the Hospital Pharmacy Departments. We have conducted an in vitro experimental study in order to test the toxicity of gentamicin, amikacin, cefazolin, ceftazidime, vancomycin, colistimethate sodium and imipenem-cilastatin eye drops; their cytotoxicity and acute tissue irritation have been evaluated. Cell-based assays were performed on human stromal keratocytes, using a cell-based impedance biosensor system [xCELLigence Real-Time System Cell Analyzer (RTCA)], and the Hen's Egg Test for the ocular irritation tests. All the eye drops, except for vancomycin and imipenem, have shown a cytotoxic effect dependent on concentration and time; higher concentrations and longer exposure times will cause a steeper decline in the population of stromal keratocytes. Vancomycin showed a major initial cytotoxic effect, which was reverted over time; and imipenem appeared as a non-toxic compound for stromal cells. The eye drops with the highest irritating effect on the ocular surface were gentamicin and vancomycin. Those antibiotic eye drops prepared at the Hospital Pharmacy Departments included in this study were considered as compounds potentially cytotoxic for the ocular surface; this toxicity was dependent on the concentration used.
El uso de reformulaciones de antibioticos parenterales en forma de colirios de composicion o concentraciones no comercializadas, comunmente denominados colirios antibioticos reforzados, es una practica habitual en oftalmologia a nivel hospitalario. El objetivo del presente trabajo ha consistido en evaluar la toxicidad ocular in vitro de los principales colirios antibioticos reforzados elaborados en los Servicios de Farmacia Hospitalaria. Hemos realizado un estudio experimental in vitro para evaluar la toxicidad de los colirios de gentamicina, amikacina, cefazolina, ceftazidima, vancomicina, colistimetato de sodio e imipenem- cilastatina en el que se ha evaluado su citotoxicidad y la irritacion tisular aguda. Los ensayos celulares se realizan sobre queratocitos estromales humanos, mediante la utilizacion de un sistema biosensor de impedancia celular [(xCELLigence Real- Time System Cell Analyzer (RTCA)] y los ensayos de irritacion ocular mediante el ensayo Hen/s Egg Test. Todos los colirios, excepto vancomicina e imipenem, han mostrado un efecto citotoxico de concentracion y tiempo dependiente, siendo las concentraciones mas altas y los tiempos mas prolongados los que provocan un descenso mas pronunciado en la poblacion de queratocitos estromales. La vancomicina muestra un importante efecto citotoxico inicial que revierte con el transcurso del tiempo y el imipenem se muestra como un compuesto no toxico para las celulas estromales. Los compuestos con mayor efecto irritante para la superficie ocular son la gentamicina y la vancomicina. Los colirios antiinfecciosos elaborados en los Servicios de Farmacia Hospitalaria estudiados se muestran como compuestos potencialmente citotoxicos para la superficie ocular, siendo esta toxicidad dependiente de la concentracion utilizada.
Asunto(s)
Antibacterianos/efectos adversos , Lesiones Oculares/inducido químicamente , Animales , Antibacterianos/administración & dosificación , Bioensayo , Células Cultivadas , Embrión de Pollo , Pollos , Composición de Medicamentos , Lesiones Oculares/epidemiología , Humanos , Queratinocitos/efectos de los fármacos , Soluciones Oftálmicas , Servicio de Farmacia en HospitalRESUMEN
This research aims towards developing an alternative therapy against Cryptosporidium parvum using bioadhesive paromomycin and diloxanide furoate-loaded microspheres. Microspheres were prepared using chitosan and poly(vinyl alcohol) and two types of cyclodextrins (ß-CD and DM-ß-CD) for the potential use of treating cryptosporidiosis. This pathogen is associated with gastrointestinal illness in humans and animals. Microparticle formulations were characterized in terms of size, surface charge, drug release and morphology. In vivo bioadhesion properties of CHI/PVA microspheres were also evaluated in mice. Finally, the in vivo efficacy of CHI/PVA microspheres against C. parvum was tested in neonatal mouse model. In this work, microspheres prepared by spray-drying showed spherical shape, diameters between 6.67±0.11 and 18.78±0.07µm and positively surface charged. The bioadhesion studies demonstrated that MS remained attached at +16h (post-infection) to the intestinal cells as detected by fluorescence. This finding was crucial taking use of the fact that the parasite multiplication occurs between 16 and 20h post-infection. The efficacy of treatment was determined by calculating the number of oocysts recovered from the intestinal tract of mice after 7days of post-infection. Mice receiving orally administered microspheres with and without drug exhibited significantly lower parasite loads compared with the control mice. Ultrastructural observations by TEM bring to light the uptake of smallest particles by enterocytes associated with conspicuous changes in enterocytic cells. Completely recovery of cell morphology was detected after 24h of first inoculation with MS. CHI/PVA microspheres appear to be a safe and simple system to be used in an anticryptosporidial treatment. The distinctive features of neonatal mice requires further work to determine the suppressive effect of this particulate delivery system on C. parvum attachment in other animal models.
Asunto(s)
Antiprotozoarios/administración & dosificación , Criptosporidiosis/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , Furanos/administración & dosificación , Microesferas , Paromomicina/administración & dosificación , Adhesividad , Animales , Animales Recién Nacidos , Antiprotozoarios/química , Antiprotozoarios/uso terapéutico , Quitosano/química , Criptosporidiosis/parasitología , Cryptosporidium parvum/efectos de los fármacos , Cryptosporidium parvum/aislamiento & purificación , Ciclodextrinas/química , Composición de Medicamentos , Liberación de Fármacos , Fluoresceína-5-Isotiocianato/química , Furanos/química , Furanos/uso terapéutico , Intestinos/química , Ratones , Oocistos/efectos de los fármacos , Carga de Parásitos , Paromomicina/química , Paromomicina/uso terapéutico , Alcohol Polivinílico/químicaRESUMEN
No disponible
Asunto(s)
Humanos , Soluciones Oftálmicas/farmacología , Composición de Medicamentos/métodos , Estabilidad de Medicamentos , Servicios FarmacéuticosRESUMEN
Non-steroidal anti-inflammatory drug (NSAID) eye drops are widely used to treat ocular inflammatory conditions related to ophthalmic surgical procedures, such as pseudophakic cystoid macular edema, and they have been used for off-label treatments. The most commonly used NSAIDs are diclofenac and ketorolac and the new molecules bromfenac and nepafenac have also been used. We used primary human keratocytes in cell culture in combination with a novel technology that evaluates dynamic real-time cytotoxicity through impedance analysis. This study also included classic cell viability tests (WST-1(®) and AlamarBlue(®)), wound healing assay, Hen's Egg Test and an ex vivo histopathological assay. NSAIDs were shown to have important cytotoxicities and to retard the healing response. Furthermore, the new eye drops containing bromfenac and nepafenac were more cytotoxic than the more classical eye drops. Nevertheless, no immuno-histochemical changes or acute irritation processes were observed after the administration of any eye drops tested. Due to cytotoxicity and the total absence of discomfort and observable injuries after the administration of these drugs, significant corneal alterations, such as corneal melts, can develop without any previous warning signs of toxicity.
Asunto(s)
Antiinflamatorios no Esteroideos/toxicidad , Supervivencia Celular/efectos de los fármacos , Queratinocitos/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Células Cultivadas , Pollos , Impedancia Eléctrica , Humanos , Queratinocitos/metabolismo , Edema Macular/prevención & control , Soluciones Oftálmicas , Seudofaquia/prevención & control , Pruebas de Toxicidad/métodosRESUMEN
Gellan gum, kappa-carrageenan and alginates are natural polysaccharides able to interact with different cations that can be used to elaborate ion-activated in situ gelling systems for different uses. The interaction between fluid solutions of these polysaccharides and cations presents into the tear made these biopolymers very interesting to elaborate ophthalmic drug delivery systems. The main purpose of this study is to evaluate the ability of mixtures of these polymers to obtain ion-activated ophthalmic in situ gelling systems with optimal properties for ocular use. To achieve this purpose different proportion of the biopolymers were analyzed using a mixture experimental design evaluating their transparency, mechanical properties and bioadhesion in the absence and presence of simulated tear fluid. Tear induces a rapid sol-to-gel phase transition in the mixtures forming a consistent hydrogel. The solution composed by 80% of gellan gum and 20% kappa-carrageenan showed the best mechanical and mucoadhesive properties. This mixture was evaluated for rheological behavior, microstructure, cytotoxicity, acute corneal irritancy, ex-vivo and in vivo ocular toxicity and in vivo corneal contact time using Magnetic Resonance Images (MRI) techniques. Result indicates that the system is safe at ophthalmic level and produces an extensive ocular permanence higher than 6h.
Asunto(s)
Carragenina/química , Sistemas de Liberación de Medicamentos/métodos , Ojo/efectos de los fármacos , Hidrogeles/química , Polisacáridos Bacterianos/química , Administración Oftálmica , Animales , Carragenina/farmacocinética , Carragenina/toxicidad , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Fenómenos Químicos , Pollos , Ojo/metabolismo , Ojo/patología , Humanos , Queratinocitos/efectos de los fármacos , Imagen por Resonancia Magnética , Masculino , Microscopía Electrónica de Rastreo , Transición de Fase , Polisacáridos Bacterianos/farmacocinética , Polisacáridos Bacterianos/toxicidad , Ratas Sprague-Dawley , Reología , Propiedades de Superficie , Lágrimas/químicaRESUMEN
The aim of the present review is to give an overview of a new class of polysaccharidic CD-based systems and to address the use of these systems in drug delivery. First, we review miscellaneous methods to obtain and synthesize the structural modification of natural polysaccharides, mainly, with cyclodextrins. In a second part of this review, we provide a summary of recent findings not only in the field of drug delivery, but in also how these systems have displayed different applications in the biomedical and pharmaceutical fields.
Asunto(s)
Ciclodextrinas/síntesis química , Portadores de Fármacos/síntesis química , Sistemas de Liberación de Medicamentos/métodos , Nanopartículas/química , Ciclodextrinas/farmacología , Portadores de Fármacos/química , Portadores de Fármacos/farmacología , Humanos , Estructura MolecularRESUMEN
For years, great efforts have been made by scientists to construct various novel interlocked supramolecular systems. A wide range of pseudorotaxanes and rotaxanes, full of challenging constructions and potential applications in areas such as nanostructured functional materials, molecular switches, molecular logic gates, molecular wires, memory devices Willner and biomedical applications have been reported recently. Cyclodextrin polyrotaxantes or polypseudorotaxanes there are not only nice and interesting supramolecular architectures but they also have a high interest for biomaterials application that allow to opened up new approaches for tissue regeneration, drug and gene delivery. The use of the supramolecular cyclodextrins complexes has given rise to interesting studies to design and develop new biomaterials with advanced properties. In this review we will update the recent advances in the use of CDs-supramolecular structures for develop new and advanced drug and gene delivery systems and for use in tissue engineering.